
The Clinical Research and Equipment industry is up 2.6% in the last week, with Locus Cell up 10%. Meanwhile, EirGenix actually underperformed within the industry, shrinking 6.3% in the last week. The industry has been flat over the past 12 months despite the gain this week.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 28 May 2026 | NT$32.0b | NT$2.7b | -NT$746,869,000.00 | 21x | -42.9x | 12.1x |
| Sat, 25 Apr 2026 | NT$35.3b | NT$2.5b | -NT$767,980,000.00 | 21.9x | -46x | 14.1x |
| Mon, 23 Mar 2026 | NT$31.4b | NT$2.5b | -NT$747,966,000.00 | 20.6x | -41.9x | 12.5x |
| Wed, 18 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Fri, 16 Jan 2026 | NT$35.3b | NT$2.4b | -NT$689,929,000.00 | 25.1x | -51.1x | 14.5x |
| Sun, 14 Dec 2025 | NT$35.6b | NT$2.4b | -NT$670,921,000.00 | 21.3x | -53x | 14.5x |
| Tue, 11 Nov 2025 | NT$34.7b | NT$2.5b | -NT$870,437,000.00 | 17.4x | -39.9x | 14.1x |
| Thu, 09 Oct 2025 | NT$38.1b | NT$2.5b | -NT$870,437,000.00 | 19.2x | -43.8x | 15.5x |
| Sat, 06 Sep 2025 | NT$35.9b | NT$2.5b | -NT$819,216,000.00 | 20.4x | -43.8x | 14.6x |
| Mon, 04 Aug 2025 | NT$33.4b | NT$2.5b | -NT$600,003,000.00 | 21.5x | -55.7x | 13.6x |
| Wed, 02 Jul 2025 | NT$33.0b | NT$2.5b | -NT$600,003,000.00 | 22.9x | -55x | 13.4x |
| Fri, 30 May 2025 | NT$33.9b | NT$2.5b | -NT$600,003,000.00 | 22.7x | -56.5x | 13.8x |
| Sun, 27 Apr 2025 | NT$31.1b | NT$2.5b | -NT$540,128,000.00 | 23.7x | -57.6x | 12.6x |
| Tue, 25 Mar 2025 | NT$36.1b | NT$2.4b | -NT$560,979,000.00 | 29.4x | -64.4x | 15x |
| Thu, 20 Feb 2025 | NT$37.3b | NT$2.6b | -NT$854,432,000.00 | 23.6x | -43.6x | 14.5x |
| Sat, 18 Jan 2025 | NT$37.1b | NT$2.6b | -NT$854,432,000.00 | 23.2x | -43.4x | 14.5x |
| Mon, 16 Dec 2024 | NT$33.7b | NT$2.6b | -NT$854,432,000.00 | 24.8x | -39.4x | 13.1x |
| Wed, 13 Nov 2024 | NT$41.2b | NT$2.5b | -NT$712,402,000.00 | 24x | -57.9x | 16.4x |
| Fri, 11 Oct 2024 | NT$41.6b | NT$2.3b | -NT$836,610,000.00 | 21.8x | -49.7x | 18.3x |
| Sun, 08 Sep 2024 | NT$40.3b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -48.1x | 17.7x |
| Tue, 06 Aug 2024 | NT$37.9b | NT$2.1b | -NT$797,765,000.00 | 29.8x | -47.5x | 17.7x |
| Thu, 04 Jul 2024 | NT$45.3b | NT$2.1b | -NT$797,765,000.00 | 34.2x | -56.8x | 21.2x |
| Sat, 01 Jun 2024 | NT$41.0b | NT$2.1b | -NT$797,765,000.00 | 32.4x | -51.4x | 19.2x |
| Mon, 29 Apr 2024 | NT$39.4b | NT$2.1b | -NT$914,899,000.00 | 31.6x | -43.1x | 18.6x |
| Wed, 27 Mar 2024 | NT$40.0b | NT$2.1b | -NT$903,875,000.00 | 31.2x | -44.2x | 18.9x |
| Fri, 23 Feb 2024 | NT$43.8b | NT$2.1b | -NT$610,218,000.00 | 33.3x | -71.7x | 21.1x |
| Sun, 21 Jan 2024 | NT$44.2b | NT$2.1b | -NT$610,218,000.00 | 32.9x | -72.5x | 21.3x |
| Tue, 19 Dec 2023 | NT$48.7b | NT$2.1b | -NT$610,218,000.00 | 33.1x | -79.8x | 23.5x |
| Thu, 16 Nov 2023 | NT$48.3b | NT$2.1b | -NT$587,339,000.00 | 31.6x | -82.2x | 23.3x |
| Sat, 14 Oct 2023 | NT$47.7b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -95.8x | 21.4x |
| Mon, 11 Sep 2023 | NT$43.1b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -86.5x | 19.4x |
| Wed, 09 Aug 2023 | NT$46.4b | NT$2.5b | -NT$278,764,000.00 | 43.7x | -166.6x | 18.8x |
| Fri, 07 Jul 2023 | NT$48.9b | NT$2.5b | -NT$274,767,000.00 | 43.1x | -178x | 20x |
| Sun, 04 Jun 2023 | NT$50.0b | NT$2.5b | -NT$274,899,000.00 | 43.7x | -181.8x | 20.2x |
-181.8x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 10.52% | |
| Healthcare | 1.00% | |
| Life Sciences | 0.078% | |
| Clinical Research and Equipment | 0.078% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6891 Locus Cell | NT$54.20 | 12.4% +NT$1.2b | 150.9% | PS851.2x | |
| 6986 HeXun Biosciences | NT$60.70 | 1.2% +NT$32.2m | -16.6% | PE25x |